1. Determinants of survival of adolescents receiving antiretroviral therapy in the Centre Region of Cameroon: a multi-centered cohort-analysis
- Author
-
Nicholas Tendongfor, Joseph Fokam, Collins Ambe Chenwi, Fabrice Léo Tamhouo Nwabo, Armanda Nangmo, Njume Debimeh, Suzie Tetang Ndiang Moyo, Marie Patrice Halle, Anne-Esther Njom-Nlend, Paul Koki Ndombo, and Alexis Ndjolo
- Subjects
HIV ,Survival ,Adolescent ,ART ,Rural ,Urban ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Abstract Background In spite of the global decreasing mortality associated with HIV, adolescents living with HIV (ADLHIV) in sub-Saharan Africa still experience about 50% mortality rate. We sought to evaluate survival rates and determinants of mortality amongst ADLHIV receiving antiretroviral therapy (ART) in urban and rural settings. Methods A multi-centered, 10-year retrospective, cohort-study including ADLHIV on ART ≥ 6 months in the urban and rural settings of the Centre Region of Cameroon. Socio-demographic, clinical, biological, and therapeutic data were collected from files of ADLHIV. The Kaplan–Meier method was used to estimate survival probability after ART initiation; the log rank test used to compare survival curves between groups of variables; and the Cox proportional hazard model was used to identify the determinants of mortality. Results A total of 403 adolescents’ records were retained; 340 (84%) were from the urban and 63 (16%) from the rural settings. The female to male ratio was 7:5; mean age (Standard deviation) was 14.1 (2.6) years; at baseline, 64.4% were at WHO clinical stages I/II, 34.9% had ≥ 500 CD4 cells/mm3, 91.1% were anemic, and the median [Inter Quartile Range] duration on ART was5.3 [0.5–16] years. The survival rate at 1, 5 and 10 years on ART was respectively 97.0%, 55.9% and 8.7%; with mean survival time of 5.8 years (95% CI 5.5–6.1). In bivariate analysis, living in the rural setting, non-disclosed HIV status, baseline CD4 count
- Published
- 2023
- Full Text
- View/download PDF